Wayback Machine
Nov DEC Jan
Previous capture 21 Next capture
2014 2015 2016
1 captures
21 Dec 15 - 21 Dec 15
sparklines
Close Help
Paclitaxel plus Bevacizumab is a Feasible Option for Chemoresistant SCLC

Summary

Salvage treatment combining paclitaxel and bevacizumab was feasible and improved outcomes in heavily pretreated patients with advanced, chemoresistant small cell lung cancer (SCLC) in a small single-center study conducted by the Hellenic Oncology Research Group. Safety concerns were an issue with these patients, who had poor prognoses and few treatment options.

  • Oncology Clinical Trials
  • Respiratory Cancers
  • Cancer
  • Oncology
  • Oncology Clinical Trials
  • Respiratory Cancers
  • Cancer
View Full Text